Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TOUR006 · 2 trials · 10 indications
Evaluates the change from baseline in hs-CRP comparing TOUR006 and placebo
| Arm | Type | Description |
|---|---|---|
| TOUR006 - 50 MG | EXPERIMENTAL | 50 mg administered subcutaneously at Day 1 and Day 90 (Placebo administered at 30, 60, 120, and 150 Day timepoints) |
| TOUR006 - 25 MG | EXPERIMENTAL | 25 mg administered subcutaneously at Day 1 and Day 90 (Placebo administered at 30, 60, 120, and 150 Day timepoints) |
| TOUR006 - 15 MG | EXPERIMENTAL | 15 mg administered subcutaneously at Days 1, 30, 60, 90, 120, and 150 |
| Placebo | PLACEBO_COMPARATOR | Administered subcutaneously at Days 1, 30, 60, 90, 120, and 150 |
| TOUR006 - 20 MG | EXPERIMENTAL | In part A of the study, participants will receive a total of three 20 mg subcutaneous injections: 1 injection every 8 weeks (Day 1, Week 8, Week 16) followed by treatment in part B of the study based on proptosis response and rescue therapy use. |
| Name | Type | Description |
|---|---|---|
| TOUR006 - 50 MG | DRUG | TOUR006 50 MG |
| TOUR006 - 25 MG | DRUG | TOUR006 25 MG |
| TOUR006 - 15 MG | DRUG | TOUR006 15 MG |
| Placebo | OTHER | Placebo |
| TOUR006 - 20 MG | DRUG | TOUR006 20 MG |
Inclusion Criteria: * Age ≥18 years at time of ICF signature. * Serum hs-CRP level ≥2.0 mg/L and \<15 mg/L * Diagnosis of chronic kidney disease, eGFR ≥15 and \<60 mL/min/1.73 m2 or eGFR ≥60 mL/min/1.73m2 and UPCR\>200 mg/g * Received COVID-19 vaccine at least 30 days prior to the Screening visit, ...
TOUR006 is an investigational small molecule being studied for chronic kidney disease and thyroid eye disease. It is in Phase 2 clinical development for both indications. In chronic kidney disease, it is being evaluated in patients with elevated high-sensitivity C-reactive protein, and in thyroid eye disease, it is being studied in participants aged 18 to 80 years.
TOUR006 is being developed by Tourmaline Bio, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol TRML. The company is conducting clinical trials to evaluate the safety and efficacy of TOUR006 in chronic kidney disease and thyroid eye disease.
TOUR006 is in Phase 2 clinical development. It is being studied in two separate Phase 2 trials: one for thyroid eye disease and one for chronic kidney disease with elevated high-sensitivity C-reactive protein. The drug is investigational and has not been approved by regulatory authorities.
TOUR006 is being studied in two Phase 2 clinical trials. NCT06088979 evaluates its efficacy and safety in participants with thyroid eye disease, with an enrollment of 79. NCT06362759 evaluates it in patients with chronic kidney disease and elevated high-sensitivity C-reactive protein, with an enrollment of 143. Both trials are randomized, double-blind, and placebo-controlled.
Yes, TOUR006 - 20 MG is an alternative name for TOUR006. The drug is also referred to by this name, which likely indicates a specific dosage form or strength. Both names refer to the same investigational drug being developed by Tourmaline Bio, Inc.
The specific molecular target of TOUR006 is not disclosed in the available information. The drug is described as a small molecule, but its mechanism of action has not been publicly detailed. Clinical trials are evaluating its effects in chronic kidney disease and thyroid eye disease.